Great Lakes Advisors LLC Makes New Investment in Elanco Animal Health Incorporated $ELAN

Great Lakes Advisors LLC acquired a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 467,485 shares of the company’s stock, valued at approximately $9,415,000.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ELAN. SJS Investment Consulting Inc. increased its holdings in shares of Elanco Animal Health by 2,563.5% in the third quarter. SJS Investment Consulting Inc. now owns 1,385 shares of the company’s stock valued at $28,000 after purchasing an additional 1,333 shares in the last quarter. Whittier Trust Co. of Nevada Inc. grew its position in shares of Elanco Animal Health by 80.3% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock worth $42,000 after buying an additional 900 shares during the period. Farther Finance Advisors LLC grew its holdings in Elanco Animal Health by 79.3% during the third quarter. Farther Finance Advisors LLC now owns 2,151 shares of the company’s stock valued at $43,000 after purchasing an additional 951 shares during the period. First Horizon Advisors Inc. grew its holdings in shares of Elanco Animal Health by 184.3% in the 2nd quarter. First Horizon Advisors Inc. now owns 3,724 shares of the company’s stock valued at $53,000 after buying an additional 2,414 shares during the period. Finally, Caitong International Asset Management Co. Ltd increased its holdings in shares of Elanco Animal Health by 261.6% in the second quarter. Caitong International Asset Management Co. Ltd now owns 4,039 shares of the company’s stock worth $58,000 after acquiring an additional 2,922 shares in the last quarter. 97.48% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts have recently commented on ELAN shares. Wall Street Zen upgraded Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a report on Monday, January 19th. Barclays started coverage on shares of Elanco Animal Health in a research report on Tuesday, December 9th. They issued an “overweight” rating and a $30.00 target price for the company. Weiss Ratings reissued a “sell (d+)” rating on shares of Elanco Animal Health in a research report on Monday, December 29th. JPMorgan Chase & Co. upgraded Elanco Animal Health from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $18.00 to $24.00 in a report on Tuesday, October 7th. Finally, Argus upgraded Elanco Animal Health from a “hold” rating to a “buy” rating and set a $25.00 target price on the stock in a report on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $25.11.

Insider Activity at Elanco Animal Health

In other news, CEO Jeffrey N. Simmons bought 22,000 shares of the stock in a transaction dated Thursday, December 11th. The shares were bought at an average price of $21.75 per share, for a total transaction of $478,500.00. Following the completion of the purchase, the chief executive officer owned 167,000 shares in the company, valued at approximately $3,632,250. This trade represents a 15.17% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Robert M. Vanhimbergen purchased 6,950 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The shares were purchased at an average cost of $21.64 per share, with a total value of $150,398.00. Following the completion of the acquisition, the chief financial officer owned 124,233 shares in the company, valued at $2,688,402.12. The trade was a 5.93% increase in their position. The SEC filing for this purchase provides additional information. Over the last three months, insiders have bought 43,450 shares of company stock valued at $937,883. 0.89% of the stock is currently owned by insiders.

Elanco Animal Health Stock Up 0.4%

ELAN opened at $24.22 on Friday. The stock’s fifty day simple moving average is $22.99 and its 200 day simple moving average is $20.24. Elanco Animal Health Incorporated has a 1-year low of $8.02 and a 1-year high of $25.29. The stock has a market cap of $12.03 billion, a PE ratio of 403.65, a price-to-earnings-growth ratio of 3.35 and a beta of 1.87. The company has a current ratio of 2.40, a quick ratio of 1.23 and a debt-to-equity ratio of 0.59.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Wednesday, November 5th. The company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.13 by $0.06. The firm had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.09 billion. Elanco Animal Health had a net margin of 0.78% and a return on equity of 7.41%. The company’s quarterly revenue was up 10.4% on a year-over-year basis. During the same period in the previous year, the company earned $0.13 earnings per share. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. As a group, research analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.